Efavirenz and CYP2B6 polymorphism:: Implications for drug toxicity and resistance

被引：38
|
作者：
Nolan, D
Phillips, E
Mallal, S
机构：
[1] Murdoch Univ, Ctr Clin Immunol & Biomed Stat, Royal Perth Hosp, Perth, WA 6000, Australia
[2] Univ British Columbia, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V5Z 1M9, Canada
来源：
CLINICAL INFECTIOUS DISEASES | 2006年 / 42卷 / 03期
关键词：
D O I：
10.1086/499369
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：408 / 410
页数：3
相关论文
共 50 条
  • [1] Pharmacokinetics of Plasma Efavirenz and CYP2B6 Polymorphism in Southern Chinese
    To, Kin Wang
    Liu, Shui Teng
    Cheung, Siu Wai
    Chan, D. Pui Chung
    Chan, R. Chiu Yeung
    Lee, Shui Shan
    [J]. THERAPEUTIC DRUG MONITORING, 2009, 31 (04) : 527 - 530
  • [2] Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro
    Desta, Zeruesenay
    Saussele, Tanja
    Ward, Bryan
    Blievernicht, Julia
    Li, Lang
    Klein, Kathrin
    Flockhart, DavidA
    Zanger, Ulrich M.
    [J]. PHARMACOGENOMICS, 2007, 8 (06) : 547 - 558
  • [3] CYP2B6 GENETIC VARIATION AND EFAVIRENZ AUTOINDUCTION INFLUENCES CYP2B6 A ACTIVITY AND EFAVIRENZ EXPOSURE IN HEALTHY VOLUNTEERS
    Metzger, I. F.
    Lu, J. B.
    Kreutz, Y.
    Thong, N.
    Flockhart, D. A.
    Desta, Z.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S80 - S80
  • [4] Optimizing efavirenz treatment:: CYP2B6 genotyping or therapeutic drug monitoring?
    Rotger, Margalida
    Telenti, Amalio
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 64 (04) : 335 - 336
  • [5] Optimizing efavirenz treatment: CYP2B6 genotyping or therapeutic drug monitoring?
    Margalida Rotger
    Amalio Telenti
    [J]. European Journal of Clinical Pharmacology, 2008, 64 : 335 - 336
  • [6] Crystal Structure of CYP2B6 in Complex with an Efavirenz Analog
    Shah, Manish B.
    Zhang, Qinghai
    Halpert, James R.
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (04)
  • [7] Efavirenz intoxication due to a new CYP2B6 constellation
    Anagnostopoulos, Alexia
    Rotger, Margalida
    Aouri, Manel
    Kuster, Stefan P.
    Telenti, Amalio
    Decosterd, Laurent A.
    Guenthard, Huldrych F.
    [J]. ANTIVIRAL THERAPY, 2013, 18 (05) : 739 - 743
  • [8] Effects of the CYP2B6*6 Allele on Catalytic Properties and Inhibition of CYP2B6 In Vitro: Implication for the Mechanism of Reduced Efavirenz Metabolism and Other CYP2B6 Substrates In Vivo
    Xu, Cong
    Ogburn, Evan T.
    Guo, Yingying
    Desta, Zeruesenay
    [J]. DRUG METABOLISM AND DISPOSITION, 2012, 40 (04) : 717 - 725
  • [9] The role of CYP2B6 516G>T polymorphism on efavirenz/nevirapine toxicity. Implications on treatment outcomes Lessons from Botswana
    Maseng, Monkgomotsi J.
    Tawe, Leabaneng
    Thami, Prisca K.
    Moyo, Sikhulile
    Kasvosve, Ishmael
    Novitsky, Vladimir
    Essex, Max
    Russo, Gianluca
    Gaseitsiwe, Simani
    Paganotti, Giacomo M.
    [J]. MEDICINE, 2022, 101 (17) : E29066
  • [10] The impact of CYP2B6 polymorphisms on the interactions of efavirenz with lumefantrine: Implications for paediatric antimalarial therapy
    Zakaria, Zaril
    Badhan, Raj K. S.
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 119 : 90 - 101
12345